Raymond James lowered the firm’s price target on Omega Healthcare (OHI) to $42 from $44 and keeps an Outperform rating on the shares. Omega Healthcare posted strong Q1 results and increased 2025 guidance that bracketed expectations, the analyst tells investors in a research note. The otherwise “pristine” quarter was marred by issues at Genesis, which failed to pay rent/interest in March, though did pay in April and also May, and is expected to pay in June, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare, Sunbound announce strategic partnership
- Omega Healthcare Revises Operator Updates Slide
- Omega Healthcare Investors Reports Strong Q1 2025 Results
- Omega Healthcare Investors: Strong Growth Amid Challenges
- Positive Outlook for Omega Healthcare: Strong Financial Performance and Strategic Developments Justify Buy Rating